Statera Biopharma, Inc. (NASDAQ: STAB) reported preliminary unaudited volume of $1,487,036 for 2021. Michael K. Handley, the STAB CEO, says the company's 'clinical-stage pipeline' has it well-positioned to achieve 'numerous milestones' in 2022.

This clinical-stage biopharmaceutical company is studying the treatment of pediatric Crohn's Disease. It is also researching the treatment of patients with acute COVID-19 infection.

Investors should put STAB stock on their Watch Lists as biopharmaceutical companies performing clinical-stage research are rising in valuation

STAB PROCEEDS FROM REGISTERED OFFERINGS TO FUND STUDIES

Handley adds, "Following the recent submission to the FDA of our Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn's Disease, we plan to use proceeds from our registered direct offering to initiate patient enrollment in the second quarter."

Those dollars will also be used to add enrollment of patients with acute COVID-19 infection in its STAT-205 study. STAB hopes to develop preliminary data from that study this year.

STAB RELEASES 2021 FINANCIAL RESULTS

One catalyst for the company is its infrastructure building. Here are the highlights of its new financials:

- Volume increased 100% to $1,487,036 following the acquisition of ImQuest Life Sciences, Inc., and its subsidiaries (ImQuest) in June 2021 by Old Cytocom.

- Due to the acquisition, the cost of revenues related to the transaction was $488,314. Cost of revenues accounted for some 33% as a percentage of revenues for 2021.

- R&D expense rose in 2021 to $31,587,000, or 191% higher than its $10,501,668 in 2020.

- The increase in R&D was a result of increased costs for the expanded clinical trial programs of Crohn's disease and COVID-19 in 2021.

- Other Expenses also rose for 2021 to $4,328,823, a 172% YOY rise. This was primarily due to an increase of $5,458,954 in interest and offset by an increase of $2,772,324 in gains on extinguishment of debt.

- Net loss for 2021 was $34,892,762, a 189% jump from the comparable period in 2020.

HANDLEY, STAB CEO, OPTIMISTIC ABOUT 2022 PERFORMANCE

"We have taken numerous steps to further the development of our clinical-stage pipeline that has us well-positioned to achieve numerous milestones in 2022," says Michael K. Handley, CEO.

STAB is developing novel immunotherapies targeting autoimmune, neutropenia/anemia emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.

STAB ADDS TO ITS BOARD

STAB has also added to its Board Satish Chandran, He is Ph.D., President and CEO of Lays Sciences, Inc. and CEO of Physis Pharma, Inc. Steve Barbarick resigned as Director and will transition to an advisory role.

"We are thrilled to welcome Dr. Chandran, a biotechnology veteran with more than 30 years experience, in drug, biologicals and medical device product development and commercialization, to our board at this exciting time as Statera Biopharma advances our pipeline toward several clinical milestones," says Handley, President and CEO.

Dr. Chandran, adds, "Statera Biopharma is poised to reach several clinical milestones in 2022, which will benefit patients with conditions ranging from Crohn's disease to SARS-CoV-2 viral infections."

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at https://www.staterabiopharma.com/

Disclaimers: TopNewsGuide 'TNG' is responsible for the production and distribution of this content. TNG is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by TNG is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall TNG. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by TNG., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. TNG. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, TNG., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. TNG has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

CONTACT: Mark McKelvie

editor@topnewsguide.com

(754) 233-0966

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE